Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jianqin Lu has a total of 149 co-authors. Here are the top co-authors by number of shared publications:

  • Song Li

    University of Pittsburgh

    13 shared publications
  • Yixian Huang

    13 shared publications
  • Jiang Li

    Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA; University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA

    11 shared publications
  • Xiang Gao

    Department of Nutrition and Food Hygiene, School of Public Health, Institute of Nutrition, Fudan University, Shanghai, China

    10 shared publications
  • Zhiren Wang

    Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, USA

    10 shared publications
  • Raman Venkataramanan

    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA

    9 shared publications

Latest Publications

  • Neddylation Blockade Potentiates Camptothecin Nanotherapy for Synergistic Topoisomerase I Inhibition in Advanced Colorectal Cancer

    by Mengwen Li, Wenpan Li, Yanhao Jiang, Elliott Brumbaugh, Leyla Estrella Cordova, Jianqin Lu

    Camptothecin (CPT) is a potent Topoisomerase I (TOP1) inhibitor that induces DNA damage through the formation of TOP1-DNA–protein cross-links (TOP1-DPCs). Despite its promising anticancer activity, the clinical translation of CPT has been limited by lactone instability, rapid clearance, off-target toxicities, and unfavorable pharmacokinetics. To overcome these limitations, we previously developed Camptothesome, a sphingomyelin-conjugated CPT nanovesicle that stabilizes the active lactone form of CPT, prolongs circulation, enhances tumor accumulation, and improves therapeutic efficacy against colorectal cancer (CRC). However, cancer cells can repair TOP1-DPCs through a neddylation-dependent pathway, reducing their sensitivity to CPT. To address this mechanism, we developed C-pevosome, a dual-drug liposomal nanoplatform that codelivers CPT and the NEDD8-activating enzyme inhibitor pevonedistat (PEV) at an optimized synergistic ratio. By simultaneously inducing TOP1-DPC formation and blocking neddylation-mediated repair, C-pevosome enhanced DNA damage, apoptosis, tumor accumulation, and antitumor efficacy while reducing systemic toxicity. To further improve intratumoral delivery, we engineered AzC-pevosome by incorporating a tumor-acidic pH-responsive charge-reversal phospholipid, which promoted cellular uptake, tumor penetration, and intratumoral distribution. Consequently, AzC-pevosome further enhanced therapeutic efficacy and sensitized tumors to immune checkpoint blockade, resulting in superior tumor suppression in advanced orthotopic CRC models. This strategy holds strong potential to improve therapeutic efficacy, safety, and patient compliance in CRC treatment.

  • Open Access

    Strategic integration of saturated phospholipids into Camptothesome to enhance colorectal cancer chemo-immunotherapy

    by Mengwen Li, Wenpan Li, Zhiren Wang, Yanhao Jiang, Elliott Shaw Brumbaugh, Leyla Estrella Cordova, Jianqin Lu

    Colorectal cancer (CRC) remains largely unresponsive to immune checkpoint blockade (ICB), with therapeutic benefit confined to a small subset of high immunogenic tumors, underscoring the need for effective combination strategies. Chemotherapy-induced immunogenic cell death (ICD) combined with immune modulation offers a promising therapeutic strategy for malignant cancers, including CRC; however, its clinical translation remains constrained by poor drug solubility, suboptimal pharmacokinetics, inadequate tumor delivery, and systemic toxicity. Previously, we developed Camptothesome-based co-delivery nanosystem that integrates a doxorubicin-indoximod (DOX-IND) conjugate with a sphingomyelin-derived camptothecin (SM-CPT), which simultaneously induced robust ICD and blocked indoleamine 2,3-dioxygenase 1 (IDO1)-mediated immunosuppression, enhancing anti-CRC efficacy. However, this formulation failed to produce sufficient efficacy in more advanced orthotopic CRC tumors. Here, we report a rational phospholipid engineering strategy to optimize this nanoplatform by incorporating four FDA-approved phospholipids, DOPC, DSPC, HSPC, and SPC at varying molar ratios to systematically tune bilayer physicochemical properties. Saturated phospholipids (DSPC and HSPC), markedly enhanced cellular uptake, IDO1 inhibition, ICD induction, and T cell proliferation. Among them, DSPC-containing nanoformulation was superior in co-delivering payloads to tumor, and boosted antitumor efficacy and immune responses in advanced metastatic CRC mouse model. Furthermore, the DSPC-fortified DOX-IND/Camptothesome potentiated the ICB to eradicate the more advanced and immune-cold CRC tumors. These findings establish phospholipid-driven membrane engineering as a key determinant of Camptothesome-based chemo-immunotherapy performance and provide a clinically translatable strategy to enhance ICB responsiveness in CRC.

  • Open Access

    Artificial recombinant high-density protein nanocarriers for precision drug delivery

    by Wenpan Li, Nan Jia, Mengwen Li, Yanhao Jiang, Jianqin Lu

    Chemically programmable reconstituted HDL nanocarriers for drug delivery.

  • Open Access

    Boosting immunogenic tumour cell death via nanotherapeutic targeting of the Stanniocalcin 1 phagocytosis checkpoint for enhanced cancer immunotherapy

    by Wenpan Li, Zhiren Wang, Mengwen Li, Yanhao Jiang, Shuang Wu, Leyla Cordova, MinHyeok Kim, Jianqin Lu

    Eliciting calreticulin (CRT) surface exposure is essential for triggering immunogenic cell death (ICD). However, stanniocalcin 1 (STC1) suppresses CRT translocation by sequestering it within mitochondria, limiting ICD induction in tumours. Here, we show that silencing STC1 enhances CRT surface exposure in Lewis lung carcinoma (LLC) cells when combined with paclitaxel (PTX), converting dying tumour cells into an in-situ vaccine that drives immunoprevention of tumour growth. To maximize this therapeutic synergy, we engineered a nanoplatform co-delivering siSTC1 and PTX, in which PTX is covalently conjugated to a sphingolipid and siSTC1 is electrostatically encapsulated (siSTC1/LNP-PTX). This system improves pharmacokinetics, synchronizes co-delivery to tumours, and enhances intratumoral exposure. Consequently, it amplifies CRT expression, promotes antigen-presenting cell-mediated phagocytosis and antigen presentation, and elicits robust cytotoxic T cell responses in LLC models. Moreover, siSTC1/LNP-PTX sensitizes tumours to PD-1 blockade. Our nanosystem, which unlocks ICD potential by silencing STC1, represents a paradigm-shifting approach to cancer immunotherapy.


  • Open Access

    Biomimetic liposomes in drug delivery: from design mechanisms to applications

    by Zhi Li, Mengwen Li, Jianqin Lu

    This review summarizes advances in biomimetic liposome-based delivery systems, highlighting design strategies such as membrane integration and applications in targeted therapy, imaging, immunomodulation, gene delivery, and vaccines.


  • Open Access

    A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer

    by Zhiren Wang, Wenpan Li, Yanhao Jiang, Teng Ma, Mengwen Li, Shuang Wu, Tuyen Ba Tran, Leyla Estrella Cordova, Ethan Lin, Aaron James Scott, et al.

    Taxol and Abraxane, the US Food and Drug Administration-approved paclitaxel (PTX) formulations, have revealed hypersensitivity due to excipients and mediocre efficacy due to insufficient tumor penetration, respectively. Here we developed a sphingolipid-derived PTX nanovesicle (paclitaxome) via covalently conjugating PTX to sphingomyelin, which improved pharmacokinetics and enhanced efficacy in metastatic triple-negative breast cancer and pancreatic cancer female mice and reduced myelosuppression. To bolster tumor penetration and reduce phagocytosis, we engineered a cationization-enabled transcytosis machinery by installing an ultra-pH-sensitive azepane (AZE) probe into paclitaxome and masked nanovesicle surface with a CD47 ‘self’ peptide (CD47p). The resulting CD47p/AZE–paclitaxome synchronized the co-delivery of gemcitabine or carboplatin to boost tumor inhibition and eradicate metastasis in late-stage KPC-Luc pancreatic cancer model and prevent tumor relapse and extend survival in postsurgical 4T1-Luc2 triple-negative breast cancer model in female mice. CD47p/AZE–paclitaxome also outperformed previous promising PTX nanoformulations. Finally, the series of nanoparticle modifications was applied to camptothecin, demonstrating its generalizability.


  • Open Access

    Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines

    by Mengwen Li, Wenpan Li, Zhi Li, Jianqin Lu

    Peptide-based vaccines only contain peptide epitopes and exclude unnecessary biological materials, which greatly reduces the risk of causing an undesired immune response and further improves the safety profile, garnering considerable interest in vaccine development. However, the immunogenicity induced by these peptides alone is not potent enough to elicit an effective immune response. Recently, combining the adjuvants with peptide antigens has shown promising effects to realize a satisfying immune response. In this review, we discuss the development of immunoadjuvants to enhance the safety and efficacy of peptide-based vaccines. The emphasis is placed on the application and clinical translation of nanotechnology-based adjuvants, highlighting the associated challenges and exploring future directions.


  • Enhanced delivery of camptothecin to colorectal carcinoma using a tumor-penetrating peptide targeting p32

    by Yanhao Jiang, Zhiren Wang, Wenpan Li, Teng Ma, Mengwen Li, Shuang Wu, Ethan Lin, Karlie Elizabeth Flader, Mengjiao Ma, Mengyang Chang, et al.


  • Liposome‐Enabled Nanomaterials for Muscle Regeneration

    by Shuang Wu, Jianqin Lu

    Muscle regeneration is a vital biological process that is crucial for maintaining muscle function and integrity, particularly for the treatment of muscle diseases such as sarcopenia and muscular dystrophy. Generally, muscular tissues can self‐repair and regenerate under various conditions, including acute or chronic injuries, aging, and genetic mutation. However, regeneration becomes challenging beyond a certain threshold, particularly in severe muscle injuries or progressive diseases. In recent years, liposome‐based nanotechnologies have shown potential as promising therapeutic strategies for muscle regeneration. Liposomes offer an adaptable platform for targeted drug delivery due to their cell membrane‐like structure and excellent biocompatibility. They can enhance drug solubility, stability, and targeted delivery while minimizing systemic side effects by different mechanisms. This review summarizes recent advancements, discusses current applications and mechanisms, and highlights challenges and future directions for possible clinical translation of liposome‐based nanomaterials in the treatment of muscle diseases. It is hoped this review offers new insights into the development of liposome‐enabled nanomedicine to address current limitations.


  • Open Access

    Size-transformable nanotherapeutics for cancer therapy

    by Teng Ma, Tuyen Ba Tran, Ethan Lin, Stephanie Hunt, Riley Haveman, Kylie Castro, Jianqin Lu